Core Insights - PharmAla Biotech Holdings Inc. has signed a distribution agreement with Veridion Group to act as the exclusive distributor for its LaNeo MDMA in the Netherlands market [1] - The partnership aims to ensure safe and controlled access to MDMA treatments for New Zealand clinicians [2][3] - Dr. Kiyan Afzali has been appointed as a director for PharmAla Australia, bringing nearly a decade of experience in translational research and drug discovery [4][5] Company Overview - PharmAla is focused on the research, development, and manufacturing of MDXX class molecules, including MDMA, and aims to alleviate the backlog of clinical-grade MDMA for trials and commercial sales [6] - The company is the only provider of clinical-grade MDMA for patient treatments outside of clinical trials and has completed proof-of-concept research into several drug candidates [6] Strategic Developments - The distribution agreement with Veridion includes an annual purchase minimum, waived for the first year, and restrictions on re-export [2] - Dr. Afzali's appointment is effective October 1, 2025, and is expected to enhance PharmAla's research and development efforts in Australia [5]